Charite Research Organisation GmbH
- Address
- lock Available on a paid plan
Oncology
Charité Research Organisation advances cancer care by testing innovative therapies for a wide range of solid tumors and hematologic malignancies.
- Advanced melanoma
- Non‑small cell lung cancer
- Colorectal cancer
- Breast cancer (HER2‑positive and HER2‑low)
- High‑grade serous ovarian cancer
- Renal cell carcinoma
- Lymphoma (diffuse large B‑cell, Hodgkin’s, peripheral T‑cell)
The trials aim to evaluate efficacy and safety of targeted agents and immunotherapies, helping to improve treatment outcomes for patients across Berlin and beyond.
Immunology & Autoimmune Disorders
Research at Charité focuses on immune‑mediated diseases, exploring new biologics that modulate the immune response.
- Atopic dermatitis
- Plaque psoriasis
- Ulcerative colitis
- Crohn’s disease
- Systemic lupus erythematosus
- Chronic inflammatory demyelinating polyneuropathy
These studies assess whether novel agents can reduce disease activity and improve quality of life for individuals living with chronic inflammation.
Metabolic & Endocrine Disorders
The site conducts trials targeting metabolic health, including obesity and diabetes management.
- Type 2 Diabetes Mellitus
- Obesity
- Metabolic syndrome
- Nutritional deficiencies
Objectives include testing agents that promote weight loss, improve glycemic control, and address associated cardiovascular risk factors.
Cardiovascular and Respiratory Diseases
Charité’s program evaluates therapies for cardiopulmonary conditions, aiming to alleviate symptoms and slow disease progression.
- Chronic obstructive pulmonary disease (COPD)
- Mild to moderate asthma
- Hypertension
- Heart failure
The research measures functional improvement, reduction in exacerbations, and overall patient well‑being.
Infectious Diseases
Studies at Charité address serious bacterial infections and sepsis, testing new antimicrobial strategies.
- Clostridioides difficile infection
- Sepsis
- Septic shock
Trials focus on safety and efficacy of novel antibiotics or adjunctive therapies to improve survival and recovery rates.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 25 therapeutic areas and 15 of 162 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 161 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 36 by active trials.
- 1Novartis Pharma AG4active
lock +35 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +21 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Charite Research Organisation GmbH
lock Showing 1 of 134 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients with Partial Lipodystrophy | Chiesi Farmaceutici S.p.A. | Phase III | Recruiting | Dec 2023 | — |
IMP list
lock Showing 1 of 162 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 13 | Unknown | 2017-06-08 | 2025-11-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.